Buscar
Congreso SOLACI
HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

Ver Categoría

Coronary disease

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat...
solaci -
Ver más
Coronary disease

SOLACI-CACI 2021 | Overcoming Challenges of the BALLOON EXPANDABLE TAVI Cases – EDWARDS Symposium

✔️ Watch again the Edwards Lifesciences Symposium in the SOLACI-CACI 2021 Virtual Congress.✔️ Topic: Overcoming Challenges of...
solaci -
Ver más
Coronary disease

The Long Marathon of Ultrathin vs. 2nd Generation Thin-Strut DES

After 2.5 years of non-stop racing, ultrathin-strut drug-eluting stents (DES) reached the finish line before 2nd generation...
solaci -
Ver más
Coronary disease

Novel DES Technology Promises to Become the Next DES Generation

The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a...
solaci -
Ver más
Acute coronary syndromes

06/22 – SOLACI Event | Round Table: Ultrathin-Struts Stents as an Approach to Acute Coronary Syndrome

solaci -
Ver más
Coronary disease

EuroPCR 2021 | CASTLE: Orsiro vs Xience Guided by Intravascular Imaging

According to the CASTLE trial, the Orsino stent—a biodegradable, ultrathin, sirolimus-eluting stent—provides the same results at 12 months...
solaci -
Ver más
Chronic Ischemic cardiopathy

EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development

According to this recent meta-analysis of randomized studies, ultrathin strut devices are associated with lower rates of...
solaci -
Ver más
Chronic Ischemic cardiopathy

EuroPCR 2021 | FUTURE II: Bioresorbable Scaffolds Reloaded

A new sirolimus-eluting bioresorbable scaffold with far thinner struts resulted non inferior to the Xience as to...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad